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Background: The BioFreedom and BioMatrix stents have an identical stent platform and eluting drug but use different drug carrier systems: 
nonpolymer (NP) or biodegradable polymer (BDP). The aim of this study was to evaluate potential impact of the different carrier systems on short- 
and mid-term vascular responses to the Biolimus A9-eluting stents (BES).
Methods: Volumetric IVUS was performed at 4-6 months (short term) in 44 lesions treated with standard-dose BioFreedom (NP, n=13) or BioMatrix 
(BDP, n=31), and at 12 months (mid term) in 25 lesions treated with NP (n=15) or BDP (n=10). To assess gross coverage of struts, a neointima-free 
frame ratio (number of frames without neointima / total frame number) was also calculated.
Results: Either stent showed no difference in vessel or peri-stent plaque volume between short and mid terms. Despite an increase in neointimal 
volume in NP from short to mid term, maximum cross sectional narrowing (max CSN) and incidence of max CSN>50% at 12 months were 
comparable between the 2 stents. Compared with BDP, NP showed a significantly lower neointima-free frame ratio at short term, which further 
decreased at mid term.
Conclusions: TCompared with biodegradable polymer-based BES, the novel polymer-free BES achieved earlier and greater extent of neointimal 
coverage without increasing significant lumen encroachment by neointima. The different carrier systems appear to affect distribution and time 
course of neointimal hyperplasia following BES implantation. 
IVUS measurements at follow-up
BioFreedom BioMatrix P Value
% Neointimal volume
Short-term 1.9±1.6 2.8±4.0 0.42
Mid-term 11.0±7.5 3.8±4.3 0.0115
P Value 0.0002 0.52
Maximum CSN, %
Short-term 8.8±6.6 12.7±11.9 0.28
Mid-term 20.0±12.1 17.3±16.1 0.64
P Value 0.0067 0.33
Max CSN > 50%, n (%)
Short-term 0 (0) 1 (3.2) 0.51
Mid-term 1 (6.7) 1 (10.0) 0.76
P Value 0.34 0.39
Neointimal-free frame ratio, %
Short-term 40.1 ± 22.1 63.6 ± 28.0 0.0105
Mid-term 5.4 ± 9.2 54.3 ± 26.1 <0.0001
P Value <0.0001 0.36
